AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31095438 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibodies against Ro52, Ro60, and La in SS patients
Number of subjects: 0
Study 31095438 — intervention group
Group type: COMPARATOR
Intervention: Autoantibodies against Ro52, Ro60, and La in ICIS patients
Number of subjects: 0
Study 31095438 — intervention group
Group type: COMPARATOR
Intervention: Autoantibodies against Ro52 and La in APECED patients
Number of subjects: 0
Study 31095438 — intervention group
Group type: COMPARATOR
Intervention: Ro60 autoantibodies in APECED patients with sicca
Number of subjects: 0
Study 31095438 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity against BPIFA1, BPIFA2/PSP, and lactoperoxidase in APECED patients
Number of subjects: 0
Study 31095438 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum autoantibodies against BPIFA1 in APECED patients with sicca
Number of subjects: 0
Study 31095438 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum autoantibodies against BPIFA2/PSP in APECED patients with sicca
Number of subjects: 0
Study 31095609 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoalbuminemia (P-Alb < 34g/L)
Number of subjects: 178
Study 31095609 — intervention group
Group type: COMPARATOR
Intervention: Normal albumin levels (P-Alb ≥ 34g/L)
Number of subjects: 178
Study 31095609 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in P-Alb levels
Number of subjects: 178
Study 31095609 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline P-Alb levels
Number of subjects: 178
Study 31095609 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted odds ratios for death at 90 days
Number of subjects: 178
Study 31095831 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for identifying inpatient overdose/oversedation events
Number of subjects: 235
Study 31096006 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) therapy
Number of subjects: 1601
Study 31096006 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) therapy with sustained virologic response (SVR)
Number of subjects: 1601
Study 31096937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) at 1.5 g/kg/day, days 1-3, with mFOLFOX6 or FOLFIRI
Number of subjects: 36
Study 31096937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) at 0.2-1.5 g/kg, 3-h infusion, once daily, days 1-3, with mFOLFOX6 or FOLFIRI
Number of subjects: 36
Study 31096937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA)
Number of subjects: 36
Study 31096944 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted community-based intervention including parent workshops on nutrition and physical activity, school-based nutrition lessons, enhanced physical education, and monthly vouchers for fruits and vegetables.
Number of subjects: 700
Study 31096944 — intervention group
Group type: COMPARATOR
Intervention: Comparison community (no intervention).
Number of subjects: 700
Study 31096979 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest (2 mg/daily)
Number of subjects: 100
Study 31097024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent nivolumab for 12 weeks; 5 patients (36%) met criteria for intermittent phase with a median tumor burden decrease of 46%; all agreed to intermittent therapy.
Number of subjects: 14
Study 31097024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent nivolumab; acceptance rate for intermittent therapy was 100% among those eligible (5 out of 5).
Number of subjects: 14
Study 31097027 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge
Number of subjects: 78
Study 31097027 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise challenge in ambient temperature
Number of subjects: 78
Study 31097027 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise challenge in cold chamber (ECC)
Number of subjects: 78
Study 31097161 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR >0.80 group with lesions having ≥3 HRPC
Number of subjects: 299
Study 31097161 — intervention group
Group type: COMPARATOR
Intervention: FFR ≤0.80 group
Number of subjects: 299
Study 31097161 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of lesions with ≥3 HRPC
Number of subjects: 299
Study 31097161 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR and number of HRPC
Number of subjects: 299
Study 31097161 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ≥3 HRPC
Number of subjects: 299
Study 31097294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (10 mg/70 kg)
Number of subjects: 10
Study 31097294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study 31097487 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine introduction
Number of subjects: 116871
Study 31097627 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol (NOX-A12) with bendamustine and rituximab
Number of subjects: 28
Study 31098625 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum to transitional milk
Number of subjects: 33
Study 31098625 — intervention group
Group type: COMPARATOR
Intervention: Mature milk compared to colostrum
Number of subjects: 33
Study 31098625 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation period
Number of subjects: 33
Study 31098682 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 26
Study 31098986 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretative phenomenological analysis (IPA) method applied to semi-structured face-to-face interviews
Number of subjects: 5
Study 31098986 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal recovery paradigm
Number of subjects: 5
Study 31099092 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternity waiting home
Number of subjects: 0
Study 31099092 — intervention group
Group type: COMPARATOR
Intervention: No maternity waiting home (control)
Number of subjects: 0
Study 31099252 — intervention group
Group type: EXPERIMENTAL
Intervention: AMD11070 (an orally administered CXCR4 entry inhibitor)
Number of subjects: 0
Study 31099895 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP450 activities assessed after a single oral administration of a cocktail of probe drugs
Number of subjects: 73
Study 31099895 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A2 and CYP2C9 activities
Number of subjects: 73
Study 31099895 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 and CYP2E1 activities
Number of subjects: 73
Study 31100122 — intervention group
Group type: EXPERIMENTAL
Intervention: WHIV
Number of subjects: 34
Study 31100122 — intervention group
Group type: COMPARATOR
Intervention: Non-HIV-infected women
Number of subjects: 34
Study 31100456 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission-time equivalents (RTE) for symptom severity or treatment-related risk
Number of subjects: 812
Study 31100456 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of active symptoms
Number of subjects: 812
Study 31100456 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of corticosteroid use
Number of subjects: 812
Study 31100456 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of risks of cancer, infection or surgery
Number of subjects: 812
Study 31100700 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training of the affected dorsiflexors for 6 weeks
Number of subjects: 20
Study 31101048 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip replacement (THR) patients
Number of subjects: 30
Study 31101048 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 30
Study 31101095 — intervention group
Group type: EXPERIMENTAL
Intervention: Community garden participation
Number of subjects: 160
Study 31101095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no community gardening)
Number of subjects: 160
Study 31101367 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stenosis <70%
Number of subjects: 51
Study 31101367 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid plaques of intermediate severity
Number of subjects: 51
Study 31101367 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender and systemic factors (hypercholesterolemia, lower GFR)
Number of subjects: 51
Study 31101422 — intervention group
Group type: EXPERIMENTAL
Intervention: emm75 GAS doses applied by swab to the pharynx
Number of subjects: 0
Study 31101422 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics treatment for all participants
Number of subjects: 0
Study 31101489 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin in combination with R-CHP (cyclophosphamide, doxorubicin, prednisone)
Number of subjects: 85
Study 31101489 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin in combination with G-CHP (obinutuzumab, cyclophosphamide, doxorubicin, prednisone)
Number of subjects: 85
Study 31101489 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Number of subjects: 85
Study 31101577 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (1 to 5 mg daily)
Number of subjects: 77
Study 31101596 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin magnifier with polarized light (SMP)
Number of subjects: 73
Study 31101596 — intervention group
Group type: COMPARATOR
Intervention: Advanced dermoscope
Number of subjects: 73
Study 31101691 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic signature (SPECTRA Score) combining decrease in STL, density and computed texture analysis of the DLL at baseline and 2-month CT
Number of subjects: 491
Study 31101691 — intervention group
Group type: COMPARATOR
Intervention: RECIST1.1 criteria
Number of subjects: 491
Study 31102044 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection (FMD) protocol including full-mouth scaling and root planing within 24 hours, application of chlorhexidine digluconate (CHX) gel in pockets and tongue plus CHX rinses for 14 days
Number of subjects: 54
Study 31102113 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-guided pulmonary vein isolation (OAI group)
Number of subjects: 70
Study 31102113 — intervention group
Group type: COMPARATOR
Intervention: Conventional contact force-guided pulmonary vein isolation (CON group)
Number of subjects: 70
Study 31102143 — intervention group
Group type: EXPERIMENTAL
Intervention: Immuno-Oncology (IO) treatments
Number of subjects: 0
Study 31102143 — intervention group
Group type: COMPARATOR
Intervention: Standard parametric models
Number of subjects: 0
Study 31102143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cure, parametric mixture and response-based landmark models
Number of subjects: 0
Study 31102144 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 155 U administered every 12 weeks
Number of subjects: 716
Study 31102144 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA treatment
Number of subjects: 716
Study 31103027 — intervention group
Group type: EXPERIMENTAL
Intervention: Airflow obstruction group
Number of subjects: 201
Study 31103027 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with exacerbation
Number of subjects: 201
Study 31103027 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with airflow obstruction
Number of subjects: 201
Study 31103027 — intervention group
Group type: COMPARATOR
Intervention: Overall health status decline
Number of subjects: 201
Study 31103379 — intervention group
Group type: EXPERIMENTAL
Intervention: qSOFA-based triage procedure
Number of subjects: 678
Study 31103379 — intervention group
Group type: COMPARATOR
Intervention: Standard triage procedures only (baseline)
Number of subjects: 678
Study 31103489 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-modal training (SMT, n=10)
Number of subjects: 20
Study 31103489 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal training (MMT, n=10)
Number of subjects: 20
Study 31103489 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SMT and MMT
Number of subjects: 20
Study 31104307 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid organ transplant recipients (sOTRs)
Number of subjects: 2758
Study 31104495 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic biomarkers associated with incident HF (discovery phase)
Number of subjects: 286
Study 31104495 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic biomarkers associated with incident HF (replication phase)
Number of subjects: 286
Study 31104495 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanistic pathways underlying incident HF
Number of subjects: 286
Study 31104505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (experimental migraine trigger)
Number of subjects: 28
Study 31104505 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan (6 mg s.c.)
Number of subjects: 28
Study 31104505 — intervention group
Group type: COMPARATOR
Intervention: No migraine-specific rescue medication
Number of subjects: 28
Study 31104544 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) for boys at 10th and 50th percentiles of HDI
Number of subjects: 6548
Study 31104544 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) for girls at 10th and 50th percentiles of HDI
Number of subjects: 6548
Study 31104544 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) for girls at 90th percentile of HDI
Number of subjects: 6548
Study 31104544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time for boys at 10th percentile of HDI
Number of subjects: 6548
Study 31104544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time for girls
Number of subjects: 6548
Study 31104545 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Training (HIFT)
Number of subjects: 20
Study 31104619 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive CPAP adherence program
Number of subjects: 90
Study 31104821 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting BVS
Number of subjects: 1002
Study 31104850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk-fat percentage intake
Number of subjects: 2890
Study 31104850 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of cow's milk consumed
Number of subjects: 2890
Study 31106141 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Parametric Quantitative Magnetic Resonance Imaging
Number of subjects: 0
Study 31106576 — intervention group
Group type: EXPERIMENTAL
Intervention: Young-onset dementia
Number of subjects: 0
Study 31106576 — intervention group
Group type: COMPARATOR
Intervention: Late-onset dementia
Number of subjects: 0
Study 31106841 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 balloon-expandable transcatheter heart valve (THV)
Number of subjects: 276
Study 31106898 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea, single oral dose of 20 mg/kg, followed by PK-guided dosing
Number of subjects: 50
Study 31106898 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea, PK-guided dosing
Number of subjects: 50
Study 31106898 — intervention group
Group type: COMPARATOR
Intervention: Traditional weight-based dosing
Number of subjects: 50
Study 31107260 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) system for propofol administration with BIS target between 40 and 50
Number of subjects: 163
Study 31107300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside reverse transcriptase inhibitors
Number of subjects: 154
Study 31107300 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitors
Number of subjects: 154
Study 31107300 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors
Number of subjects: 154
Study 31107300 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrase inhibitors (yes or no)
Number of subjects: 154
Study 31107300 — intervention group
Group type: COMPARATOR
Intervention: Control group (CSVD-free PLHIVs)
Number of subjects: 154
Study 31107351 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS-sCPIS
Number of subjects: 51
Study 31107351 — intervention group
Group type: COMPARATOR
Intervention: sCPIS
Number of subjects: 51
Study 31107869 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug therapy (IVM + DEC + ALB)
Number of subjects: 56
Study 31107956 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin treatment
Number of subjects: 0
Study 31108015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruzasvir 180 mg plus uprifosbuvir 450 mg once daily for 12 weeks
Number of subjects: 282
Study 31108163 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-administered KSADS-COMP
Number of subjects: 669
Study 31108163 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth self-administered KSADS-COMP
Number of subjects: 669
Study 31108163 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent self-administered KSADS-COMP
Number of subjects: 669
Study 31108264 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitters (participants who had not used for at least 30 days at follow-up)
Number of subjects: 115
Study 31108264 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic participants (newly or persistently symptomatic)
Number of subjects: 115
Study 31108264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chippers (participants with few symptoms)
Number of subjects: 115
Study 31108264 — intervention group
Group type: EXPERIMENTAL
Intervention: Converted Chippers (participants with improved symptom counts)
Number of subjects: 115
Study 31108264 — intervention group
Group type: COMPARATOR
Intervention: Quitters
Number of subjects: 115
Study 31108325 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 113
Study 31108510 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF-rich vegetables (15 g ITF/d)
Number of subjects: 26
Study 31109199 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency dTMS (20 Hz)
Number of subjects: 99
Study 31109199 — intervention group
Group type: COMPARATOR
Intervention: Sham dTMS
Number of subjects: 99
Study 31109986 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with central sleep apnoea
Number of subjects: 141
Study 31109986 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with obstructive sleep apnoea
Number of subjects: 141
Study 31109986 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without SDB
Number of subjects: 141
Study 31109986 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥70 years
Number of subjects: 141
Study 31109986 — intervention group
Group type: EXPERIMENTAL
Intervention: Central sleep apnoea
Number of subjects: 141
Study 31109986 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 141
Study 31109986 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with delirium
Number of subjects: 141
Study 31110096 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19.CAR T cells (autologous T-lymphocytes transduced by RV-SFG.CD19.CD28.4-1BB zeta retroviral vector)
Number of subjects: 0
Study 31110479 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 36
Study 31110479 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MCT)
Number of subjects: 36
Study 31110479 — intervention group
Group type: COMPARATOR
Intervention: Control (non-exercising group)
Number of subjects: 36
Study 31110648 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone 400 mg daily at bedtime from 28 weeks until delivery
Number of subjects: 70
Study 31110648 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment other than normal tonics)
Number of subjects: 70
Study 31111072 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CC16 levels on POD1
Number of subjects: 73
Study 31111072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretransplant serum CC16 levels
Number of subjects: 73
Study 31111072 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the receiver operating characteristic curves for POD1 serum CC16 levels
Number of subjects: 73
Study 31111072 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of mechanical ventilation and intensive care unit stay
Number of subjects: 73
Study 31111255 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue scale
Number of subjects: 12
Study 31111762 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS patients
Number of subjects: 2500
Study 31111762 — intervention group
Group type: EXPERIMENTAL
Intervention: MDS/MPN patients
Number of subjects: 2500
Study 31111762 — intervention group
Group type: EXPERIMENTAL
Intervention: ICUS cases
Number of subjects: 2500
Study 31111867 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt intake 1 g/d higher in Japan
Number of subjects: 4680
Study 31111867 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt intake 1 g/d higher in China
Number of subjects: 4680
Study 31111867 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt intake 1 g/d higher in the United Kingdom
Number of subjects: 4680
Study 31111867 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt intake 1 g/d higher in the United States
Number of subjects: 4680
Study 31112005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 783
Study 31112005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 783
Study 31112005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg and 10 mg
Number of subjects: 783
Study 31112005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib treatment
Number of subjects: 783
Study 31112060 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 0
Study 31112060 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study 31112389 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I
Number of subjects: 0
Study 31112389 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T
Number of subjects: 0
Study 31112476 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy followed by N-AVD (doxorubicin, vinblastine, and dacarbazine)
Number of subjects: 51
Study 31112476 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy followed by N-AVD
Number of subjects: 51
Study 31112777 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasses prescribed and provided to students
Number of subjects: 197